IL-4/IL-13 Responsive STAT6 Luciferase Reporter HEK293 Cell Line
IL-4/IL-13 Responsive STAT6 Luciferase Reporter HEK293 Cell Line is a HEK293 cell line with stably integrated Firefly luciferase reporter under the control of STAT6 response element and human STAT6 (signal transduced and activator of transcription factor 6), resulting in a fully functional STAT6 signaling pathway.
This cell line has been validated with activation assays with human IL-4 (interleukin-4) and IL-13 (interleukin-13) and the use of anti-IL-4R and anti-IL-13R antagonists.
Interested in screening and profiling inhibitors, blocking antibodies, or activators of IL-4 or IL-13 signaling without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Media Required for Cell Culture
Name | Ordering Information |
Thaw Medium 1 | BPS Bioscience #60187 |
Growth Medium 1M | BPS Bioscience #79723 |
Materials Used in Cellular Assay
Name | Ordering Information |
Thaw Medium 1 | BPS Bioscience #60187 |
Human Interleukin-4 | BPS Bioscience #90193 |
Human Interleukin-13 | BPS Bioscience #90179 |
Dupilumab Recombinant Human Monoclonal Antibody | Invitrogen #MA5-41985 |
Lebrikizumab | MedChem #HY-P99025 |
Clear-bottom, white 96-well tissue culture-treated plate | Corning #3610 |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
The transcription factor STAT6 (signal transduced and activator of transcription factor 6) plays a vitally important role in immune cells. IL-4-activated STAT6 signaling is required for Th2 differentiation and immunoglobulin class switching and it also mediates direct repression of inflammatory enhancers in macrophages. STAT6 is involved in several aspects of allergic inflammatory disease, like airway hyperresponsiveness, eosinophilic infiltration, and mast cells responses. STAT6 is activated primarily by IL-4 and the related IL-13, with have overlapping biologic profiles. Upon IL-4 and IL-13 binding, the receptor complex composed of IL-4Ralpha and IL-13Ralpha1 activates the receptor-associated Janus kinases (JAK1 and Tyk2), leading to the activation of STAT6. Activated STAT6 forms homodimers that translocate to the nucleus where they bind the promoter of responsive genes, inducing gene transcription. While both cytokines activate STAT6 signal, it has been proven that IL-4 is more potent in engaging this signaling pathway than IL-13. Dysfunction of the STAT6 pathway leads to allergic reactions (asthma, atopic dermatitis, food allergies) and cancer (Hodgkin, central nervous system, and follicular lymphoma). STAT6 can serve as a diagnostic and prognostic tool. Inhibitors have been shown to reduce acute inflammation in animal models, and future developments may lead to new therapeutical tools for STAT6 related pathologies.
Kasaian MT., et al., 2013. Am J Respir Cell Mol Biol. 49(1):37-46.
Czimmerer Z., et al., 2018. Immunity 48(1):75-90.e6.